Online inquiry

IVTScrip™ mRNA-Anti-IGF1R, CP-751871(Cap 1, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ6157MR)

This product GTTS-WQ6157MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & Pseudo-UTP. It ecodes the monoclonal antibody that targets IGF1R gene. The antibody can be applied in Non-Small Cell Lung Cancers (NSCLC) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_000875.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3480
UniProt ID P08069
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IGF1R, CP-751871(Cap 1, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ6157MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ15759MR IVTScrip™ mRNA-Anti-CA9, WX-G250(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA WX-G250
GTTS-WQ1422MR IVTScrip™ mRNA-Anti-MUC16, ACA125(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ACA125
GTTS-WQ1145MR IVTScrip™ mRNA-Anti-VEGFA, ABP 215(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA ABP 215
GTTS-WQ13176MR IVTScrip™ mRNA-Anti-TNFRSF4, PF-04518600(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA PF-04518600
GTTS-WQ13331MR IVTScrip™ mRNA-Anti-PDCD1, PF-06801591(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA PF-06801591
GTTS-WQ7850MR IVTScrip™ mRNA-Anti-RTN4, GSK-1223249(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA GSK-1223249
GTTS-WQ10073MR IVTScrip™ mRNA-Anti-FN, L19TNF(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA L19TNF
GTTS-WQ13493MR IVTScrip™ mRNA-Anti-IgG-Fc, PRTX-100(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA PRTX-100
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW